ADMS gets FDA approval as expected, stock goes up
Post# of 72440
This was expected, as they released their good Phase III results a year ago, so the stock had already priced quite a bit of the positive news into it already.
And, this is not a NEW drug, it's just a time-release formulation of an old drug.
What do you think would happen if, for instance, a small biotech released great data on a NEW type of drug? Hmmm?
Lots more than 50% up, that's my guess.